2022
Immunotherapy After Chemotherapy and Radiation for Clinical Stage III Lung Cancer
Pichert MD, Canavan ME, Maduka RC, Li AX, Ermer T, Zhan PL, Kaminski M, Udelsman BV, Blasberg JD, Park HS, Goldberg SB, Boffa DJ. Immunotherapy After Chemotherapy and Radiation for Clinical Stage III Lung Cancer. JAMA Network Open 2022, 5: e2224478. PMID: 35925606, PMCID: PMC9353596, DOI: 10.1001/jamanetworkopen.2022.24478.Peer-Reviewed Original ResearchMeSH KeywordsAgedCarcinoma, Non-Small-Cell LungCohort StudiesFemaleHumansImmunotherapyLung NeoplasmsMaleNeoplasm StagingConceptsStage III non-small cell lung cancerNon-small cell lung cancerClinical stage III non-small cell lung cancerUnresectable stage III non-small cell lung cancerPropensity-matched sampleGeneral US populationSurvival advantageCohort studyLung cancerMultivariable Cox proportional hazards modelsUS populationStage III lung cancerMedian age 66 yearsCox proportional hazards modelNational Cancer DatabaseEfficacy of immunotherapyAge 66 yearsProtocol rangesCell lung cancerClinical trial populationsProportional hazards modelTerms of ageImmunotherapy initiationImmunotherapy recipientsImmunotherapy use
2021
Prognostic impact of mismatch repair deficiency in high- and low-intermediate-risk, early-stage endometrial cancer following vaginal brachytherapy
Li JY, Park HS, Huang GS, Young MR, Ratner E, Santin A, Damast S. Prognostic impact of mismatch repair deficiency in high- and low-intermediate-risk, early-stage endometrial cancer following vaginal brachytherapy. Gynecologic Oncology 2021, 163: 557-562. PMID: 34602287, DOI: 10.1016/j.ygyno.2021.09.018.Peer-Reviewed Original ResearchConceptsRecurrence-free survivalEndometrioid endometrial cancerVaginal brachytherapyPMMR patientsOverall survivalEEC patientsEndometrial cancerExact testThree-year recurrence-free survivalEarly-stage endometrial cancerCox proportional hazards regressionPoor recurrence-free survivalAdjuvant vaginal brachytherapyThree-year OSMultivariable Cox regressionLympho-vascular invasionSignificant prognostic variablesProportional hazards regressionLog-rank testKaplan-Meier estimatesDeficient mismatch repairMismatch repair statusFisher's exact testMismatch repair deficiencyDMMR statusRates of invasive disease and outcomes in NSCLC patients with biopsy suggestive of carcinoma in situ
Talcott WJ, Miccio JA, Park HS, White AA, Kozono DE, Singer L, Sands JM, Sholl LM, Detterbeck FC, Mak RH, Decker RH, Kann BH. Rates of invasive disease and outcomes in NSCLC patients with biopsy suggestive of carcinoma in situ. Lung Cancer 2021, 157: 17-20. PMID: 34052704, DOI: 10.1016/j.lungcan.2021.05.028.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaBiopsyCarcinoma in SituCarcinoma, Non-Small-Cell LungHumansLung NeoplasmsNeoplasm StagingRetrospective StudiesConceptsNon-small cell lung cancerBiopsy suggestiveInvasive diseaseSitu diseaseSquamous histologySurvival outcomesTumor sizeObserved cohortNational Cancer DatabaseExcellent survival outcomesHalf of patientsCell lung cancerMultivariable logistic regressionResection of lesionsAdenocarcinoma histologyDefinitive therapyNSCLC patientsOverall survivalLocal therapyRisk stratificationLung cancerCancer DatabaseResectionSurgical pathologyLesion sizeEvaluation of head and neck soft tissue sarcoma 8th edition pathologic staging system and proposal of a novel stage grouping system
Lee NCJ, Eskander A, Miccio JA, Park HS, Shah C, Rutenberg M, Hosni A, Husain ZA. Evaluation of head and neck soft tissue sarcoma 8th edition pathologic staging system and proposal of a novel stage grouping system. Oral Oncology 2021, 114: 105137. PMID: 33422859, DOI: 10.1016/j.oraloncology.2020.105137.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedFemaleHead and Neck NeoplasmsHumansMaleMiddle AgedNeoplasm StagingPrognosisSarcomaConceptsNeck soft tissue sarcomasTumor size cutNational Cancer DatabaseSoft tissue sarcomasMultivariable analysisTissue sarcomasFive-year overall survivalNeoadjuvant therapy patientsT1-3 tumorsEnd Results (SEER) databaseAdjacent structuresEvaluation of headPaucity of dataNCDB cohortSEER cohortPrimary surgeryOverall survivalWorsened survivalAdverse prognosticatorPrognostic differencesResults databaseStaging systemT4 classificationTumor stageCancer Database
2020
Revisiting the Radiation Therapy Oncology Group 1221 Hypothesis: Treatment for Stage III/IV HPV-Negative Oropharyngeal Cancer
Jacobs D, Torabi SJ, Park HS, Rahmati R, Young MR, Mehra S, Judson BL. Revisiting the Radiation Therapy Oncology Group 1221 Hypothesis: Treatment for Stage III/IV HPV-Negative Oropharyngeal Cancer. Otolaryngology 2020, 164: 1240-1248. PMID: 33198564, DOI: 10.1177/0194599820969613.Peer-Reviewed Original ResearchConceptsNational Cancer DatabaseHPV-negative oropharyngeal cancersChemoradiation therapyOverall survivalCancer DatabaseOropharyngeal cancerHPV-negative oropharyngeal squamous cell carcinomaLarge national cancer databaseNeck cancer-specific survivalOropharyngeal squamous cell carcinomaCox proportional hazards regressionKaplan-Meier survival analysisCancer-specific survivalImproved overall survivalMultivariable Cox regressionRetrospective cohort studyAdjuvant chemoradiation therapyUse of surgeryEnd Results ProgramProportional hazards regressionSquamous cell carcinomaSEER cohortAdjuvant therapyCohort studySEER database
2019
Multi-Institutional Validation of Deep Learning for Pretreatment Identification of Extranodal Extension in Head and Neck Squamous Cell Carcinoma.
Kann BH, Hicks DF, Payabvash S, Mahajan A, Du J, Gupta V, Park HS, Yu JB, Yarbrough WG, Burtness BA, Husain ZA, Aneja S. Multi-Institutional Validation of Deep Learning for Pretreatment Identification of Extranodal Extension in Head and Neck Squamous Cell Carcinoma. Journal Of Clinical Oncology 2019, 38: 1304-1311. PMID: 31815574, DOI: 10.1200/jco.19.02031.Peer-Reviewed Original ResearchConceptsNeck squamous cell carcinomaExtranodal extensionSquamous cell carcinomaLymph nodesCell carcinomaContrast-enhanced CT scanDiagnostic abilityBoard-certified neuroradiologistsTreatment escalationCancer Genome AtlasPathologic confirmationPretreatment identificationDiagnostic challengeExternal validation data setsPathology resultsPretreatment imagingPoor prognosticatorClinical utilityCT scanPatientsClinical decisionHNSCCDiagnostic accuracyInstitutional ValidationGenome AtlasImpact of contralateral lymph nodal involvement and extranodal extension on survival of surgically managed HPV-positive oropharyngeal cancer staged with the AJCC eighth edition
Miccio JA, Verma V, Kelly J, Kann BH, An Y, Park HS, Eskander A, Burtness B, Husain Z. Impact of contralateral lymph nodal involvement and extranodal extension on survival of surgically managed HPV-positive oropharyngeal cancer staged with the AJCC eighth edition. Oral Oncology 2019, 99: 104447. PMID: 31630059, DOI: 10.1016/j.oraloncology.2019.104447.Peer-Reviewed Original ResearchMeSH KeywordsAgedFemaleHumansLymph NodesMaleNeoplasm StagingOropharyngeal NeoplasmsPrognosisSurvival AnalysisConceptsOropharyngeal squamous cell carcinomaExtranodal extensionLymphovascular invasionKaplan-Meier overall survival analysisContralateral lymph node involvementHPV-positive oropharyngeal cancerFuture staging systemsNational Cancer DatabaseLymph node involvementLymph nodal involvementSquamous cell carcinomaAJCC eighth editionOverall survival analysisPathologic nodalInferior OSNodal involvementNode involvementWorse OSClinical stagingPrognostic factorsOropharyngeal cancerPositive marginsPrognostic importanceCell carcinomaCox regressionClinical Outcomes of Head and Neck Cancer Patients Who Undergo Resection, But Forgo Adjuvant Therapy
LOGANADANE G, KANN BH, PARK HS, JOHNSON SB, MEHRA S, JUDSON BL, BHATIA A, BELKACEMI Y, YARBROUGH WG, BURTNESS B, HUSAIN ZA. Clinical Outcomes of Head and Neck Cancer Patients Who Undergo Resection, But Forgo Adjuvant Therapy. Anticancer Research 2019, 39: 4885-4890. PMID: 31519591, DOI: 10.21873/anticanres.13674.Peer-Reviewed Original ResearchConceptsLocoregional recurrence-free survivalAdjuvant therapyNeck squamous cell carcinomaOutcomes of patientsRecurrence-free survivalSquamous cell carcinomaNeck cancer patientsHNSCC patientsClinical outcomesRecurrence rateCell carcinomaMean TTPCancer patientsPatientsTherapyResectionMonthsOutcomesHNSCCSurgeryCarcinomaHeadIncidenceProgressionPathologic staging changes in oral cavity squamous cell carcinoma: Stage migration and implications for adjuvant treatment
Lee NCJ, Eskander A, Park HS, Mehra S, Burtness BA, Husain Z. Pathologic staging changes in oral cavity squamous cell carcinoma: Stage migration and implications for adjuvant treatment. Cancer 2019, 125: 2975-2983. PMID: 31090934, DOI: 10.1002/cncr.32161.Peer-Reviewed Original ResearchConceptsOral cavity squamous cell carcinomaPathologic extranodal extensionDepth of invasionAJCC Cancer Staging ManualCancer Staging ManualSquamous cell carcinomaOverall survivalPT3N0 patientsStage migrationStaging ManualCell carcinomaStaging systemAJCC-8 staging systemPathologic tumor classificationNational Cancer DatabaseRisk of deathNew staging systemPStage IVBUpstaged tumorsAdjuvant treatmentDefinitive surgeryExtranodal extensionPostoperative radiotherapyPT classificationPT1 tumorsMulti-institutional analysis of stereotactic body radiation therapy for operable early-stage non-small cell lung carcinoma
Kann BH, Verma V, Stahl JM, Ross R, Dosoretz AP, Shafman TD, Gross CP, Park HS, Yu JB, Decker RH. Multi-institutional analysis of stereotactic body radiation therapy for operable early-stage non-small cell lung carcinoma. Radiotherapy And Oncology 2019, 134: 44-49. PMID: 31005223, DOI: 10.1016/j.radonc.2019.01.027.Peer-Reviewed Original ResearchConceptsNon-small cell lung carcinomaStereotactic body radiation therapyProgression-free survivalEarly-stage non-small cell lung carcinomaOperable patientsBody radiation therapyCell lung carcinomaOverall survivalLocal failureLung carcinomaRadiation therapyInoperable early stage non-small cell lung carcinomaDefinitive stereotactic body radiation therapyLack of resectionPoor surgical candidacyRetrospective cohort studyKaplan-Meier methodologyHigher overall survivalDisease-related outcomesMulti-institutional analysisDocumentation of patientsStandard of careMulti-institutional studyCohort studyInoperable patients
2018
Clinical value of transoral robotic surgery: Nationwide results from the first 5 years of adoption
Li H, Torabi SJ, Park HS, Yarbrough WG, Mehra S, Choi R, Judson BL. Clinical value of transoral robotic surgery: Nationwide results from the first 5 years of adoption. The Laryngoscope 2018, 129: 1844-1855. PMID: 30575965, DOI: 10.1002/lary.27740.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, Squamous CellChemoradiotherapy, AdjuvantChi-Square DistributionCombined Modality TherapyDatabases, FactualFemaleHumansKaplan-Meier EstimateMaleMargins of ExcisionMiddle AgedMultivariate AnalysisNatural Orifice Endoscopic SurgeryNeoplasm StagingOropharyngeal NeoplasmsProportional Hazards ModelsRegression AnalysisRetrospective StudiesRobotic Surgical ProceduresTreatment OutcomeUnited StatesConceptsOropharyngeal squamous cell carcinomaTransoral robotic surgeryTransoral laser microsurgeryNonrobotic surgeryTORS patientsPositive marginsTLM patientsLower likelihoodT2 oropharyngeal squamous cell carcinomaEarly stage oropharyngeal squamous cell carcinomaLong-term oncologic outcomesUse of TORSKaplan-Meier log-rank testRobotic surgeryNational Cancer DatabaseMajority of patientsMultivariate Cox analysisSquamous cell carcinomaLog-rank testChi-square testCox multivariateN3 diseaseAdjuvant chemoradiotherapyAdjuvant radiotherapyAdjuvant therapyStereotactic body radiotherapy with adjuvant systemic therapy for early-stage non-small cell lung carcinoma: A multi-institutional analysis
Kann BH, Miccio JA, Stahl JM, Ross R, Verma V, Dosoretz AP, Park HS, Shafman TD, Gross CP, Yu JB, Decker RH. Stereotactic body radiotherapy with adjuvant systemic therapy for early-stage non-small cell lung carcinoma: A multi-institutional analysis. Radiotherapy And Oncology 2018, 132: 188-196. PMID: 30391106, DOI: 10.1016/j.radonc.2018.10.017.Peer-Reviewed Original ResearchConceptsNon-small cell lung carcinomaStereotactic body radiotherapyAdjuvant systemic therapyEarly-stage non-small cell lung carcinomaSystemic therapyMulti-institutional analysisCell lung carcinomaOverall survivalST patientsBody radiotherapyLung carcinomaDefinitive stereotactic body radiotherapyEarly-stage NSCLC patientsClinical risk factorsRetrospective cohort studyKaplan-Meier methodHigher T stageTreatment of patientsMulti-institutional databasePropensity-score matchingPlatinum doubletsST cohortST regimenCohort studyNSCLC patientsAdjuvant Chemotherapy Is Associated With Improved Survival for Late‐Stage Salivary Squamous Cell Carcinoma
Cheraghlou S, Schettino A, Zogg CK, Otremba MD, Bhatia A, Park HS, Osborn HA, Mehra S, Yarbrough WG, Judson BL. Adjuvant Chemotherapy Is Associated With Improved Survival for Late‐Stage Salivary Squamous Cell Carcinoma. The Laryngoscope 2018, 129: 883-889. PMID: 30151947, DOI: 10.1002/lary.27444.Peer-Reviewed Original ResearchMeSH KeywordsAgedCarcinoma, Squamous CellChemoradiotherapy, AdjuvantChemotherapy, AdjuvantCombined Modality TherapyFemaleHumansKaplan-Meier EstimateMaleMiddle AgedNeoplasm StagingPropensity ScoreProportional Hazards ModelsRadiotherapy, AdjuvantRetrospective StudiesSalivary Gland NeoplasmsSurvival RateTreatment OutcomeConceptsLate-stage patientsSquamous cell carcinomaAdjuvant radiotherapyAdjuvant therapyAdjuvant chemoradiotherapyAdjuvant chemotherapyImproved survivalCell carcinomaImproved long-term survivalCox survival regressionPrimary cutaneous malignanciesUnique disease entityAddition of chemotherapyNational Cancer DatabaseEarly-stage diseaseFive-year survivalEarly-stage patientsKaplan-Meier analysisParotid gland cancerLate stage groupLong-term survivalSurvival benefitCutaneous malignanciesPoor prognosisRetrospective studyAssociation Between Radiation Dose and Outcomes With Postoperative Radiotherapy for N0-N1 Non–Small Cell Lung Cancer
Wang EH, Corso CD, Park HS, Chen AB, Wilson LD, Kim AW, Decker RH, Yu JB. Association Between Radiation Dose and Outcomes With Postoperative Radiotherapy for N0-N1 Non–Small Cell Lung Cancer. American Journal Of Clinical Oncology 2018, 41: 152-158. PMID: 26523443, DOI: 10.1097/coc.0000000000000245.Peer-Reviewed Original ResearchMeSH KeywordsAcademic Medical CentersAgedCarcinoma, Non-Small-Cell LungCohort StudiesDatabases, FactualDisease-Free SurvivalDose-Response Relationship, RadiationFemaleHumansLung NeoplasmsMaleMargins of ExcisionMiddle AgedMultivariate AnalysisNeoplasm InvasivenessNeoplasm StagingPneumonectomyPrognosisProportional Hazards ModelsRadiotherapy DosageRadiotherapy, AdjuvantRadiotherapy, Intensity-ModulatedRetrospective StudiesSurvival AnalysisTreatment OutcomeConceptsNon-small cell lung cancerPostoperative radiotherapyCell lung cancerIntensity-modulated radiation therapyPORT doseOverall survivalLung cancerRadiation therapyUse of PORTNational Cancer Data BaseStage IIProportion of patientsGroup of patientsProportional hazards regressionEvidence of benefitSurgical resectionWorse survivalMultivariable analysisHazards regressionRetrospective studyConformal radiationPatientsRadiotherapy techniquesRadiation modalitiesModern treatment
2017
Treatment deintensification in human papillomavirus‐positive oropharynx cancer: Outcomes from the National Cancer Data Base
Cheraghlou S, Yu PK, Otremba MD, Park HS, Bhatia A, Zogg CK, Mehra S, Yarbrough WG, Judson BL. Treatment deintensification in human papillomavirus‐positive oropharynx cancer: Outcomes from the National Cancer Data Base. Cancer 2017, 124: 717-726. PMID: 29243245, DOI: 10.1002/cncr.31104.Peer-Reviewed Original ResearchConceptsNational Cancer Data BaseStage III diseaseTriple-modality therapyAdjuvant radiotherapyOropharyngeal cancerStage IHuman papillomavirus-positive oropharyngeal cancerUnivariate Kaplan-Meier analysisAvoidance of chemotherapyDeintensification of treatmentEdition stage IStage II diseaseMultivariate Cox regressionAmerican Joint CommitteeKaplan-Meier analysisDisease stage groupsForm of treatmentTreatment deintensificationAdjuvant chemoradiotherapyDefinitive radiotherapyTreatment intensificationFavorable prognosisImproved survivalCox regressionRetrospective studyAdjuvant Therapy Use and Survival in Stage II Endometrial Cancer
Lester-Coll NH, Young MR, Park HS, Ratner ES, Litkouhi B, Damast S. Adjuvant Therapy Use and Survival in Stage II Endometrial Cancer. International Journal Of Gynecological Cancer 2017, 27: 1904-1911. PMID: 28763364, DOI: 10.1097/igc.0000000000001095.Peer-Reviewed Original ResearchConceptsReceipt of chemotherapyEndometrioid endometrial carcinomaNational Cancer Data BaseImproved overall survivalRole of chemotherapyOverall survivalAdjuvant chemotherapyAdjuvant treatmentStage II endometrial cancerCox proportional hazards regressionPropensity scoreAdjuvant therapy useGrade 3 diseaseStage II patientsProportional hazards regressionWorse overall survivalMultivariable logistic regressionKaplan-Meier estimatesLog-rank testAdjuvant radiotherapyExcellent prognosisLymphovascular invasionObservational cohortEEC patientsEndometrial cancerUse of Alternative Medicine for Cancer and Its Impact on Survival
Johnson SB, Park HS, Gross CP, Yu JB. Use of Alternative Medicine for Cancer and Its Impact on Survival. Journal Of The National Cancer Institute 2017, 110: djx145. PMID: 28922780, DOI: 10.1093/jnci/djx145.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsBreast NeoplasmsChoice BehaviorColorectal NeoplasmsComorbidityComplementary TherapiesEducational StatusFemaleHumansIncomeLung NeoplasmsMaleNeoplasm StagingNorthwestern United StatesPacific StatesPatient PreferenceProstatic NeoplasmsResidence CharacteristicsSex FactorsSurvival RateConceptsConventional cancer treatmentsAlternative medicineColorectal cancerCox proportional hazards regressionGreater riskLower comorbidity scoreMultivariable logistic regressionProportional hazards regressionPatterns of utilizationHigher socioeconomic statusNonmetastatic breastComorbidity scoreHormone therapyCurable cancerHazards regressionLung cancerAM useAnticancer treatmentStage IICancerIndependent covariatesLogistic regressionPatientsCancer treatmentSocioeconomic statusAnnual Facility Treatment Volume and Patient Survival for Mycosis Fungoides and Sézary Syndrome
Kann BH, Park HS, Yeboa DN, Aneja S, Girardi M, Foss FM, Roberts KB, Wilson LD. Annual Facility Treatment Volume and Patient Survival for Mycosis Fungoides and Sézary Syndrome. Clinical Lymphoma Myeloma & Leukemia 2017, 17: 520-526.e2. PMID: 28655598, DOI: 10.1016/j.clml.2017.05.017.Peer-Reviewed Original ResearchConceptsMF/SSOverall survivalSézary syndromeHazard ratioImproved survivalMycosis fungoidesPatient survivalHighest quintileLowest quintileTreatment volumeImproved overall survivalMultivariable Cox regressionNational Cancer DatabaseKaplan-Meier methodAnnual patient volumeNational database analysisLog-rank testContinuous variablesMedian followMultivariable analysisCox regressionOS survivalCancer DatabasePatientsPatient volumeHypofractionated Radiotherapy for Patients with Early-Stage Glottic Cancer: Patterns of Care and Survival
Bledsoe TJ, Park HS, Stahl JM, Yarbrough WG, Burtness BA, Decker RH, Husain ZA. Hypofractionated Radiotherapy for Patients with Early-Stage Glottic Cancer: Patterns of Care and Survival. Journal Of The National Cancer Institute 2017, 109: djx042. PMID: 28521361, DOI: 10.1093/jnci/djx042.Peer-Reviewed Original ResearchConceptsEarly-stage glottic cancerOverall survivalGlottic cancerMultivariable Cox proportional hazards regressionNational Comprehensive Cancer Network guidelinesNational Cancer Data BaseCox proportional hazards regressionPropensity scoreClinical T1 diseaseImproved overall survivalHigh-volume centersProportional hazards regressionLog-rank testPatterns of careRadiation treatment schedulesLarge national databaseCT2 diseaseDefinitive radiotherapyT1 diseaseHypofractionated radiotherapyImproved survivalMultivariable analysisTreatment patternsHazards regressionNetwork guidelinesThe prognostic value of extranodal extension in human papillomavirus‐associated oropharyngeal squamous cell carcinoma
An Y, Park HS, Kelly JR, Stahl JM, Yarbrough WG, Burtness BA, Contessa JN, Decker RH, Koshy M, Husain ZA. The prognostic value of extranodal extension in human papillomavirus‐associated oropharyngeal squamous cell carcinoma. Cancer 2017, 123: 2762-2772. PMID: 28323338, DOI: 10.1002/cncr.30598.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, Squamous CellChemoradiotherapy, AdjuvantFemaleHead and Neck NeoplasmsHumansMaleMiddle AgedMultivariate AnalysisNeoplasm InvasivenessNeoplasm StagingOropharyngeal NeoplasmsOtorhinolaryngologic Surgical ProceduresPapillomaviridaePapillomavirus InfectionsPrognosisPropensity ScoreProportional Hazards ModelsRadiotherapy, AdjuvantRetrospective StudiesSquamous Cell Carcinoma of Head and NeckSurvival RateConceptsOropharyngeal squamous cell carcinomaENE-positive patientsHPV-positive oropharyngeal squamous cell carcinomaExtranodal extensionHPV-positive patientsOverall survivalPrimary surgeryPT4 tumorsAdjuvant chemoradiationConcurrent chemoradiotherapyAdjuvant treatmentPositive oropharyngeal squamous cell carcinomaPT3/pT4 tumorsMultivariable Cox regression analysisNational Cancer Data BasePredictors of OSPropensity score-matched comparisonAdjuvant concurrent chemoradiotherapyCharlson-Deyo scoreInvolved lymph nodesAdverse prognostic factorInferior overall survivalLymph node statusCox regression analysisSingle-institution study